Hanson & Doremus Investment Management Acquires New Holdings in ASP Isotopes Inc. (NASDAQ:ASPI)

Hanson & Doremus Investment Management purchased a new stake in shares of ASP Isotopes Inc. (NASDAQ:ASPI) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 6,000 shares of the company’s stock, valued at approximately $27,000.

Other large investors have also bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in ASP Isotopes during the third quarter valued at approximately $6,249,000. Telemark Asset Management LLC acquired a new stake in shares of ASP Isotopes during the 3rd quarter valued at $4,726,000. Philadelphia Financial Management of San Francisco LLC boosted its stake in shares of ASP Isotopes by 158.3% during the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 991,863 shares of the company’s stock worth $2,757,000 after acquiring an additional 607,893 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of ASP Isotopes by 389.6% in the 2nd quarter. Marshall Wace LLP now owns 545,072 shares of the company’s stock worth $1,668,000 after acquiring an additional 433,734 shares during the last quarter. Finally, GSA Capital Partners LLP raised its position in shares of ASP Isotopes by 96.0% during the third quarter. GSA Capital Partners LLP now owns 770,989 shares of the company’s stock worth $2,143,000 after purchasing an additional 377,721 shares during the period. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Stock Up 12.9 %

ASPI stock opened at $6.13 on Friday. The company has a 50 day moving average of $5.21 and a two-hundred day moving average of $4.25. The company has a quick ratio of 7.54, a current ratio of 7.55 and a debt-to-equity ratio of 0.80. ASP Isotopes Inc. has a 12-month low of $1.86 and a 12-month high of $9.33. The company has a market cap of $437.62 million, a price-to-earnings ratio of -10.05 and a beta of 3.48.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Canaccord Genuity Group started coverage on shares of ASP Isotopes in a report on Friday, October 4th. They issued a “buy” rating and a $4.50 target price for the company. Canaccord Genuity Group reissued a “buy” rating and set a $4.50 price target on shares of ASP Isotopes in a research report on Friday, October 18th.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.